Updated: Even with no primary endpoint data, TauRx still eyes Alzheimer’s filing after PhIII update
Despite its inability to conduct a Phase III primary analysis, TauRx is planning regulatory filings for its tau aggregation inhibitor in Alzheimer’s disease after reporting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.